Form 4: Ionis Pharma Exec Sells Shares Under 10b5-1 Plan

Patrick R. O'Neil, EVP CLO & General Counsel of Ionis Pharmaceuticals, exercised stock options and sold common stock totaling 64,664 shares on October 2, 2025, under a pre-arranged trading plan.

Summary

• Patrick R. O'Neil, Executive Vice President, Chief Legal Officer, and General Counsel of Ionis Pharmaceuticals, Inc. (IONS), reported transactions on October 2, 2025.
• O'Neil exercised non-qualified stock options to acquire 30,203 shares of common stock at an exercise price of $56.78 per share.
• Concurrently, O'Neil exercised non-qualified stock options to acquire an additional 34,461 shares of common stock at an exercise price of $60.89 per share.
• Following the exercise, O'Neil sold 30,203 shares of common stock at a weighted average price of $67.6892 per share, with individual sales ranging from $67.50 to $68.03.
• Additionally, O'Neil sold 34,461 shares of common stock at a weighted average price of $67.6892 per share, with individual sales ranging from $67.50 to $68.03.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by O'Neil on May 2, 2025.
• After these transactions, O'Neil beneficially owns 57,130 shares of Ionis Pharmaceuticals common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This Form 4 reports a routine, pre-planned insider transaction (exercise of options and subsequent sale) under a 10b5-1 plan. It does not reflect new information about the company's operational or financial performance, nor does it suggest a change in management's outlook. It is primarily a personal liquidity event for the executive.

Positives

• The exercise of stock options indicates that the executive realized value from their compensation package, aligning their interests with shareholder value creation over time.

Negatives

• The sale of shares by an insider, even if pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence, although this is mitigated by the 10b5-1 plan.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales were executed pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common in publicly traded companies. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, providing an affirmative defense against insider trading allegations. Such transactions are generally viewed as routine liquidity events for executives rather than signals of company-specific news, especially when pre-scheduled.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even under a 10b5-1 plan, could lead to minor short-term market speculation, but typically has limited long-term impact on shareholder value as it's a pre-arranged personal financial event.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Patrick O'Neil, 10b5-1 Plan, Executive Compensation